TG01: Additional Phase I/II data

Data from 15 evaluable patients with surgically resected pancreatic cancer in the open-label, European Phase I/II TG01-01 trial showed that 0.7 mg intradermal TG01 plus GM-CSF and gemcitabine led to a...